Business Wire - June 7, 2005
Samaritan's lead oral entry inhibitor, SP-01A, will be given to HIV-1 positive patients who are experiencing evidence of an increasing viral load despite antiretroviral treatment, to assess SP-01A's safety and effect on viral load.
Dr. Greeson, CEO of Samaritan Pharmaceuticals stated, "CROfessionals is a remarkable CRO. They are unbelievably determined to get through our Phase II trial as efficiently and timely as we are."
Sue Bhadare, CEO of CROfessionals stated, "CROfessionals is a niche CRO specializing in working with companies with limited clinical trial resources, but requiring faster paced Phase II trials.
CROfessionals has assumed the responsibility of pro-actively managing and monitoring Samaritan's trial and has a team of a Project Manager, and two Clinical Research Associates, dedicated to this study to ensure its success, with Good Clinical Practices compliance, and the meeting of its aggressive timelines."
Ms. Bhadare went on to say, "Since February of this year, Samaritan and CROfessionals has integrated into one team and we are thoroughly enjoying this tight working relationship. Together, Samaritan and CROfessionals are overcoming the usual 'start up' obstacles of conducting a clinical trial as a team. We are confident of meeting our goals."
Samaritan Pharmaceuticals: "A Cure Is Closer Than You Think."
Samaritan Pharmaceuticals is a drug development company driven to commercialize its pipeline of innovative drugs. Samaritan, in collaboration with Georgetown University, is currently advancing innovative drugs for AIDS, Alzheimer's, Cancer and Cardiovascular disease.
Visit our Web site at www.samaritanpharma.com.
Disclaimer
The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings and Web site. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K filed April 15, 2005. The company undertakes no duty to update forward-looking statements.
CONTACT: Samaritan Pharmaceuticals, Inc.
Gene Boyle, 702-735-7001
Fax: 702-737-7016
GeneBoyle@SamaritanPharma.com
SOURCE: Samaritan Pharmaceuticals, Inc.
050607
BW050608
Copyright © 2005 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .